Turkey Lung Cancer Therapeutics Market Report 2022 to 2030

Turkey Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Turkey Lung Cancer Therapeutics Market will reach a value of $462 Mn from $238 Mn in 2022, growing at a CAGR of 8.6% during 2022-30. The Lung Cancer Therapeutics Market in Turkey is dominated by a few domestic pharmaceutical companies such as Silanes, Liomont, and PISA. The Lung Cancer Therapeutics Market in Turkey is segmented into different types of cancer and different therapy types. Some of the major factors affecting the Turkey lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies, and the presence of highly efficient drugs.

ID: IN10TRPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Turkey AUTHOR: Dr. Vishwa Modhia

Buy Now

Turkey Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Turkey Lung Cancer Therapeutics market will reach a value of $462 Mn from $238 Mn in 2022, growing at a CAGR of 8.6% during 2022-30.

Turkey is an upper middle-income, developing transcontinental country located in Southeastern Europe and Southwestern Asia bordering the Black Sea. Lung cancer accounts for 17.6 % of all cancer forms in Turkey. With 41,000 new cases in 2020 and an age-adjusted incidence rate of 41.7 and 8.7 per 100,000 for men and women, Turkey ranks first. The most common subtype is non-small cell histology, which accounts for over 80% of all thoracic malignancies, half of which are adenocarcinomas, and small cell histology accounts for 16.5 %. Lung cancer detection and treatment in Turkey have advanced, as in many other nations throughout the world.

According to the most recent WHO data published in 2020, the number of lung cancer deaths in Turkey reached 35,070, accounting for 9.01 % of all deaths. Turkey ranks third in the world with an age-adjusted death rate of 39.65 per 100,000 inhabitants. Turkey's government spends 4.6% of its GDP on healthcare.

Turkey Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Currently, 14 Turkish cities have population-based cancer registry facilities, representing 50.2 % of the population. Turkey now has roughly 65,000 lung cancer patients, with a total estimated number of cancer cases related to smoking of approximately 31,000. Furthermore, Turkey benefits from an advantageous geopolitical location as well as a rapid economic rebound following COVID-19, making doing business easier. In 2022, Turkey would have 670 thoracic surgeons (0.79 per 100,000 people) conducting LC surgery in 126 institutions. Medicine prices in Turkey are incredibly low, routinely ranking lower than in several African countries. Radiation oncology is an essential component of the multidisciplinary treatment approach in Turkey. There will be 593 active radiation oncologists by December 2021. These aspects could boost Turkey's Lung Cancer Therapeutics market.

Market Restraints

Diagnostic and therapeutic facilities are not evenly accessible throughout the country, and making modern diagnostic and therapeutic facilities more accessible in rural areas is crucial. Given the high prevalence of lung carcinoma in Turkey, future goals include launching lung cancer screening programmes alongside smoking cessation programmes that are tailored to the country's requirements and resources. The manufacturing sector in Turkey is strongly reliant on imports. These factors may deter new entrants into the Turkey Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Laboratorios Silanes: Silanes is a Mexican pharmaceutical company that specializes in the development and production of innovative medicines for various health conditions, including cancer. They have a range of oncology products, including those for lung cancer
Laboratorios Liomont: Liomont is a Mexican pharmaceutical company that produces and markets a range of medicines for various therapeutic areas, including oncology
Laboratorios PISA: PISA is a Mexican pharmaceutical company that focuses on the development and production of generic medicines. They offer a range of oncology products, including those for lung cancer
Grupo Biotoscana: Biotoscana is a biopharmaceutical company that focuses on the development, production, and distribution of speciality and orphan drugs in Latin America
Rimsa: Rimsa is a Mexican pharmaceutical company that produces and distributes a range of prescription and over-the-counter medicines. They have a range of oncology products, including those for lung cancer

Healthcare Policies and Reimbursement Scenarios

The Turkish Medicines and Medical Devices Agency (TITCK) is the regulatory authority in Turkey in charge of authorising and regulating therapeutic medications. The Turkish Government's Social Security Institution (SSI) reimburses 86 % of the population in the Turkish healthcare system. Turkey boasts one of the world's most admired social security systems, providing its residents with free healthcare and access to a lengthy variety of cutting-edge cancer medications. However, with one of Europe's youngest populations, the system's sustainability is dubious as its exceptionally youthful population ages and cancer incidence rises.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.